Spina M P, Ventura M, Lavecchia G, Bombara R, Giraldi B, Mensi F, Massari A, Rossi F, Santi G, Visca U
Minerva Med. 1981 Dec 8;72(49):3323-8.
The association of lithium carbonate and antiblastic drugs has been studied in 22 patients suffering from tumours to see whether it was able to prevent or attenuate the neutropenising effect and establish whether its protection action on leucocytaemia was not just transitory but was maintained for prolonged treatment also. Patients were submitted to four oncolytic treatment cycles during which administration with LiCO3 was associated with the first and third cycles (LNLN sequence) in 14 patients and with the second and fourth (NLNL sequence) in the other 8. Statistical analysis of the results obtained confirmed that lithium carbonate performs a protective action with respect to antiblastic-induced neutropenia and that the action is long term. The drop in monocytes also seems to diminish after administration of lithium carbonate.
对22名肿瘤患者研究了碳酸锂与抗瘤药物的联合使用情况，以观察其是否能够预防或减轻中性粒细胞减少效应，并确定其对白细胞减少症的保护作用是否不仅是短暂的，而且在长期治疗中也能持续。患者接受了四个溶瘤治疗周期，在此期间，14名患者在第一个和第三个周期（LNLN序列）联合使用LiCO3，另外8名患者在第二个和第四个周期（NLNL序列）联合使用。对所得结果的统计分析证实，碳酸锂对抗瘤药物引起的中性粒细胞减少具有保护作用，且该作用是长期的。服用碳酸锂后，单核细胞的减少似乎也有所减轻。
